Herantis publishes 2H & FY 2022 Report
Herantis Pharma Plc Company Release, March 2, 2023, at 8:00 a.m. EET/7:00 a.m. CET “We made good progress in 2022 achieving encouraging preclinical results and submitting clinical trial application (CTA) for HER-096. The compelling preclinical data supports the potential of HER-096 to be a disease-modifying therapy for Parkinson’s disease with a unique mechanism of action. We look forward to the first HER-096 human dose in 1H 2023 and to create additional value in 2023 through early clinical development and to pursue partnering opportunities for HER-096. In December 2022,